Is mivamutin injection already covered by medical insurance?

Mifamurtide injection (Mifamurtide) has not yet obtained marketing approval in mainland China, and therefore has not been included in the national medical insurance catalog or local medical insurance system. The drug was first approved by the European Medicines Agency (EMA) for the treatment of patients with high-grade, non-metastatic osteosarcoma after surgical resection and combination chemotherapy, showing potential survival benefit, especially in children and young adults. Although it has been included in some medical insurance systems in European and other countries, in China, because it has not yet completed the clinical registration and marketing approval process, it is still outside the scope of "overseas drugs" outside the policy.

At present, if domestic patients want to be treated with mivamutide injection, they usually need to obtain original drugs through overseas drug purchase services, self-funded channels or cross-border medical platforms. The price of this drug is relatively high in the international market. A single dose may cost between several thousand to tens of thousands of yuan. The cost of a complete course of treatment is a huge burden on the patient's family. Since it is not covered by domestic medical insurance, the cost of the medicine cannot be reimbursed by medical insurance. This is an important factor that must be considered when making treatment decisions for patients with limited financial conditions.

Despite this, in recent years, as global drug access has accelerated, more and more overseas rare disease drugs have been gradually included in the domestic review channel. As a potential drug for treating osteosarcoma in children, mivamutide has attracted the attention of some domestic medical institutions and patient organizations. In the future, if a domestic pharmaceutical company applies for registration and completes relevant clinical trials, it may be approved for marketing in China and entered into the medical insurance directory when conditions are mature, thus improving the accessibility and economy of the drug.

All in all, mivamutin injection has not yet been launched in mainland China, nor has it been covered by medical insurance. For patients in need of treatment, consult about how to obtain drugs through legal channels, and understand the safety and cost of medication to make rational decisions.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact